Skip to main content

Ebola Virus Disease

20
Pipeline Programs
18
Companies
16
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
3
5
0
5
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1280%
Monoclonal Antibody
213%
Small Molecule
17%
+ 15 programs with unclassified modality

Competitive Landscape

18 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
5 programs
1
2
2
BioNTech - Pfizer COVID-19 vaccinePhase 4Vaccine
rVSVDG-ZEBOV-GP Ebola Virus VaccinePhase 4Vaccine
ErveboPhase 21 trial
Recombinant Vesicular Stomatitis Vaccine for EbolaPhase 2Vaccine
rVSVΔG-ZEBOV-GP, V920Phase 1/2
Active Trials
NCT05202288Not Yet Recruiting132Est. Aug 2027
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
4 programs
1
1
2
BioNTech - Pfizer COVID-19 vaccinePhase 4Vaccine1 trial
rVSVDG-ZEBOV-GP Ebola Virus VaccinePhase 4Vaccine1 trial
Recombinant Vesicular Stomatitis Vaccine for EbolaPhase 2Vaccine1 trial
rVSVΔG-ZEBOV-GP, V920Phase 1/21 trial
Active Trials
NCT05130398Completed120Est. Aug 2022
NCT06100913Active Not Recruiting30Est. Aug 2027
NCT06587503Not Yet Recruiting72Est. May 2025
+1 more trials
Alliance Pharmaceuticals
3 programs
1
2
ErveboPhase 3
vesicular stomatitis virus-Ebola vaccinePhase 3Vaccine
ErveboPhase 2
Public Health Vaccines
1 program
1
Ad26.ZEBOV, MVA-BN-Filo vaccinePhase 3Vaccine1 trial
Active Trials
NCT04152486Unknown20,426Est. Feb 2022
Response Pharmaceuticals
Response PharmaceuticalsVA - Falls Church
1 program
1
ErveboPhase 31 trial
Active Trials
NCT06841614Not Yet Recruiting160Est. Aug 2028
Allied Medical
Allied MedicalMO - St. Louis
1 program
1
ErveboPhase 3
Prevail Therapeutics
1 program
1
Ad26.ZEBOVPhase 21 trial
Active Trials
NCT02876328Completed4,789Est. Dec 2023
Syneos Health
Syneos HealthNC - Morrisville
1 program
1
AzithromycinPhase 1/21 trial
Active Trials
NCT02380625Unknown150Est. Mar 2016
Auro Vaccines
Auro VaccinesNY - Pearl River
1 program
1
Ebola Zaire VaccinePhase 1Vaccine1 trial
Active Trials
NCT02718469Completed38Est. Sep 2016
Inovio Pharmaceuticals
1 program
1
INO-4201Phase 11 trial
Active Trials
NCT04906629Completed46Est. May 2022
Eppendorf
EppendorfGermany - Hamburg
1 program
1
VSV-ZEBOVPhase 11 trial
Active Trials
NCT02296983Unknown40Est. Sep 2016
Merck & Co.
Merck & Co.RAHWAY, NJ
3 programs
Recombinant Vesicular Stomatitis Vaccine for EbolaPHASE_2Vaccine
BioNTech - Pfizer COVID-19 vaccinePHASE_4Vaccine
rVSVDG-ZEBOV-GP Ebola Virus VaccinePHASE_4Vaccine
Regeneron
RegeneronTARRYTOWN, NY
2 programs
REGN3470-3471-3479N/A1 trial
ErveboPHASE_2
Active Trials
NCT03576690Available
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
AnsuvimabN/AMonoclonal Antibody1 trial
Active Trials
NCT05067166Available
Ridgeback Biotherapeutics
1 program
AnsuvimabN/AMonoclonal Antibody
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Ebola Virus Disease Survivors: Clinical and Immunologic Follow-upN/A1 trial
Active Trials
NCT02431923Completed4,043Est. Apr 2021
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
BrincidofovirPHASE_2Small Molecule1 trial
Active Trials
NCT04268966Withdrawn0Est. Dec 2015
Sierra Sciences
1 program
ErveboPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Sharp TherapeuticsrVSVDG-ZEBOV-GP Ebola Virus Vaccine
Sharp TherapeuticsBioNTech - Pfizer COVID-19 vaccine
Response PharmaceuticalsErvebo
Public Health VaccinesAd26.ZEBOV, MVA-BN-Filo vaccine
MSDErvebo
Sharp TherapeuticsRecombinant Vesicular Stomatitis Vaccine for Ebola
Prevail TherapeuticsAd26.ZEBOV
Jazz PharmaceuticalsBrincidofovir
Sharp TherapeuticsrVSVΔG-ZEBOV-GP, V920
Syneos HealthAzithromycin
Inovio PharmaceuticalsINO-4201
Auro VaccinesEbola Zaire Vaccine
EppendorfVSV-ZEBOV
Allergy TherapeuticsEbola Virus Disease Survivors: Clinical and Immunologic Follow-up

Clinical Trials (16)

Total enrollment: 30,086 patients across 16 trials

NCT05992480Sharp TherapeuticsrVSVDG-ZEBOV-GP Ebola Virus Vaccine

REVIVE (Response to the Ebola Virus Vaccine)

Start: Dec 2025Est. completion: May 202640 patients
Phase 4Recruiting
NCT06587503Sharp TherapeuticsBioNTech - Pfizer COVID-19 vaccine

Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses

Start: Oct 2024Est. completion: May 202572 patients
Phase 4Not Yet Recruiting
NCT06841614Response PharmaceuticalsErvebo

EBOla Post-Exposure Prophylaxis

Start: Sep 2026Est. completion: Aug 2028160 patients
Phase 3Not Yet Recruiting
NCT04152486Public Health VaccinesAd26.ZEBOV, MVA-BN-Filo vaccine

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

Start: Nov 2019Est. completion: Feb 202220,426 patients
Phase 3Unknown
NCT05202288MSDErvebo

Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers

Start: Jan 2027Est. completion: Aug 2027132 patients
Phase 2Not Yet Recruiting
NCT06100913Sharp TherapeuticsRecombinant Vesicular Stomatitis Vaccine for Ebola

Immunology of Ebola Vaccine

Start: Aug 2024Est. completion: Aug 202730 patients
Phase 2Active Not Recruiting
NCT02876328Prevail TherapeuticsAd26.ZEBOV

Partnership for Research on Ebola VACcinations

Start: Mar 2017Est. completion: Dec 20234,789 patients
Phase 2Completed
NCT04268966Jazz PharmaceuticalsBrincidofovir

An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola

Start: Oct 2014Est. completion: Dec 20150
Phase 2Withdrawn
NCT05130398Sharp TherapeuticsrVSVΔG-ZEBOV-GP, V920

Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon

Start: Apr 2021Est. completion: Aug 2022120 patients
Phase 1/2Completed
NCT02380625Syneos HealthAzithromycin

Multiple Treatments for Ebola Virus Disease (EVD)

Start: Apr 2015Est. completion: Mar 2016150 patients
Phase 1/2Unknown
NCT04906629Inovio PharmaceuticalsINO-4201

INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees

Start: Sep 2021Est. completion: May 202246 patients
Phase 1Completed
NCT02718469Auro VaccinesEbola Zaire Vaccine

Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

Start: Dec 2015Est. completion: Sep 201638 patients
Phase 1Completed
NCT02296983EppendorfVSV-ZEBOV

A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.

Start: Dec 2014Est. completion: Sep 201640 patients
Phase 1Unknown
NCT03576690RegeneronREGN3470-3471-3479

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

N/AAvailable
NCT05067166BioTherapeutics IncAnsuvimab

Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP

N/AAvailable
NCT02431923Allergy TherapeuticsEbola Virus Disease Survivors: Clinical and Immunologic Follow-up

Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up

Start: Dec 2017Est. completion: Apr 20214,043 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 30,086 patients
18 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.